Summary
GE HealthCare Technologies Inc. reported a solid third quarter of 2025, demonstrating revenue growth and a significant increase in net income compared to the same period last year. Total revenues grew by 6% year-over-year, driven by robust performance across most segments, particularly Pharmaceutical Diagnostics (PDx) which saw a notable 20% increase fueled by the acquisition of Nihon Medi-Physics (NMP) and organic growth. The company also experienced strong growth in the Imaging and Advanced Visualization Solutions (AVS) segments. Despite some headwinds in the Patient Care Solutions (PCS) segment, the overall revenue trajectory is positive, indicating continued demand for GE HealthCare's diverse product and service offerings. Profitability saw a substantial improvement, with Net Income Attributable to GE HealthCare increasing by 18% for the nine-month period and by 3% for the quarter. While operating income saw a slight decrease for the quarter due to increased cost of goods sold and services impacted by inflation and tariffs, the nine-month operating income showed a healthy increase. The company's strategic focus on acquisitions, such as NMP, and ongoing investments in R&D and commercial teams, position it well for future growth. GE HealthCare's strong cash flow generation and healthy balance sheet, including increased cash reserves and managed debt levels, further underscore its financial stability.
Financial Highlights
48 data points| Revenue | $5.14B |
| Gross Profit | $1.99B |
| R&D Expenses | $292.00M |
| SG&A Expenses | $1.04B |
| Operating Expenses | $1.34B |
| Operating Income | $653.00M |
| Net Income | $446.00M |
| EPS (Basic) | $0.98 |
| EPS (Diluted) | $0.98 |
| Shares Outstanding (Basic) | 456.00M |
| Shares Outstanding (Diluted) | 457.00M |
Key Highlights
- 1Total revenues increased by 6% to $5.14 billion for the third quarter of 2025, and by 4% to $14.93 billion for the first nine months.
- 2Net income attributable to GE HealthCare increased by 18% to $1.495 billion for the first nine months of 2025, while the third quarter saw a decrease of 5% to $446 million compared to a strong prior year quarter.
- 3The Pharmaceutical Diagnostics (PDx) segment was a standout performer, with revenues up 20% for the quarter and 13% for the nine months, significantly boosted by the NMP acquisition and strong organic growth.
- 4GE HealthCare completed the acquisition of the remaining 50% interest in Nihon Medi-Physics (NMP) for $271 million, recognizing a $97 million gain on the remeasurement of its previously held interest.
- 5The company authorized a new share repurchase program for up to $1 billion, repurchasing $200 million of stock in the first nine months of 2025.
- 6Cash from operating activities for the first nine months of 2025 was $937 million, a decrease from $1.04 billion in the prior year, impacting free cash flow which decreased by 21% to $589 million.
- 7The company has a strong liquidity position with $4.03 billion in cash, cash equivalents, and restricted cash as of September 30, 2025, and access to $3.5 billion in revolving credit facilities.